Method For Suppressing Glucagon Secretion Of An Sglt2 Inhibitor

Patent No. EP3142661 (titled "Method For Suppressing Glucagon Secretion Of An Sglt2 Inhibitor") was filed by Astrazeneca on May 14, 2015. The application was issued on Oct 6, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKJul 6, 2022TER MEER STEINMEISTER & PARTNER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3142661

ASTRAZENECA
Application Number
EP15726257A
Filing Date
May 14, 2015
Status
Revoked
Jun 14, 2024
Publication Date
Oct 6, 2021